Skip to content

RNTX RNTX Change in AP

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Gilead Sciences logo
Gilead SciencesGILD
-$67M+36.2%
AbbVie logo
AbbVieABBV
-$1.59B-129%
CTO
Citius Oncology, Inc.CTOR
-$1.56M-187%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
-$3.47M+19.8%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$139K+893%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's change in AP?
RNTX (RNTX) reported change in AP of $2.29M in Q1 2026.
How has RNTX's change in AP changed year-over-year?
RNTX's change in AP increased by 861.3% year-over-year, from $238K to $2.29M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.